

# Takahiro Seki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1873699/publications.pdf>

Version: 2024-02-01

16  
papers

1,107  
citations

623188

14  
h-index

940134

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

2080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pericyteâ€“fibroblast transition promotes tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5618-27.	3.3	246
2	Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance. Cell Metabolism, 2018, 28, 104-117.e5.	7.2	191
3	Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nature Communications, 2013, 4, 2129.	5.8	94
4	Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nature Communications, 2016, 7, 12680.	5.8	89
5	Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat. Nature Communications, 2016, 7, 12152.	5.8	84
6	Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning. Journal of Experimental Medicine, 2018, 215, 611-626.	4.2	66
7	Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors. Nature Communications, 2020, 11, 3704.	5.8	62
8	Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14906-14911.	3.3	52
9	A miR-327â€“FGF10â€“FGFR2-mediated autocrine signaling mechanism controls white fat browning. Nature Communications, 2017, 8, 2079.	5.8	52
10	Dual roles of endothelial FGF-2â€“FGFR1â€“PDGF-BB and perivascular FGF-2â€“FGFR2â€“PDGFRÎ² signaling pathways in tumor vascular remodeling. Cell Discovery, 2018, 4, 3.	3.1	42
11	VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization. Cell Reports, 2014, 9, 569-580.	2.9	28
12	Switching harmful visceral fat to beneficial energy combustion improves metabolic dysfunctions. JCI Insight, 2017, 2, e89044.	2.3	28
13	CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. Scientific Reports, 2019, 9, 19384.	1.6	22
14	PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors. Science Advances, 2015, 1, e1400244.	4.7	21
15	CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. Cell Chemical Biology, 2022, 29, 572-585.e8.	2.5	18
16	Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9635-E9644.	3.3	12